FORT WORTH, Texas — American Airlines said Wednesday it plans to discontinue service between New York's John F. Kennedy International Airport and London's Stansted Airport.
The decision, coming less than a year after the service was launched, will be effective July 2. It is part of the airline's recently announced plan to cut capacity in response to rising fuel prices and a faltering economy.
These rising gas prices are really causing havoc.
5.28.2008
American cuts service between JFK, London's Stansted Airport
Nepal votes to abolish monarchy
The Himalayan nation of Nepal has become the world's newest republic, ending 240 years of monarchy.
A constituent assembly meeting in the capital, Kathmandu, overwhelmingly voted to abolish royal rule.
The Maoists, who emerged as the largest party in last month's elections, were committed to ousting King Gyanendra and creating a republic.
Good for them
5.27.2008
Porsche Files Complaint
FRANKFURT -- Porsche Automobil Holding SE Tuesday said it had filed a complaint against a decision made at Volkswagen AG's annual shareholder meeting on maintaining a controversial blocking minority, which poses a threat to Porsche's plan to take control of the company.
Porsche said its complaint, filed at a regional court in Braunschweig, Germany, is aimed at making the regulations for Volkswagen "fully reflect the judgment of the European Court of Justice," adding that the "action is aimed at clarifying the legal situation" surrounding Europe's largest auto maker by sales.
Porsche said its complaint, filed at a regional court in Braunschweig, Germany, is aimed at making the regulations for Volkswagen "fully reflect the judgment of the European Court of Justice," adding that the "action is aimed at clarifying the legal situation" surrounding Europe's largest auto maker by sales.
Alnylam Pharma, Japan's Takeda sign $1B RNAi deal
NEW YORK (Associated Press) - Biotechnology firm Alnylam Pharmaceuticals Inc. said Tuesday it formed a research partnership with Japan's Takeda Pharmaceutical Co. Ltd. potentially worth more than $1 billion.
The biotech company, which also formed a lucrative $1 billion partnership with Swiss drug maker Roche last year, is developing RNAi, or gene silencing, technology, which uses mechanisms within the body to target and "turn off" certain genes associated with cancer and other diseases.
The biotech company, which also formed a lucrative $1 billion partnership with Swiss drug maker Roche last year, is developing RNAi, or gene silencing, technology, which uses mechanisms within the body to target and "turn off" certain genes associated with cancer and other diseases.
Subscribe to:
Posts (Atom)
